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Abstract 
Background Lowe syndrome (LS) and Dent-2 disease (DD2) are disorders associated with 
mutations in the OCRL gene and characterized by progressive chronic kidney disease (CKD). 
Here, we aimed to investigate the long-term renal outcome and identify potential determinants 
of CKD and its progression in children with these tubulopathies.  
Methods Retrospective, analyses of clinical and genetic data in a cohort of 106 boys (LS: 88 
and DD2: 18). For genotype-phenotype analysis, we grouped mutations according to their 
type and localization. To investigate progression of CKD we used survival analysis by 
Kaplan-Meier method using stage 3 CKD as the end-point.  
Results Median estimated glomerular filtration rate (eGFR) was lower in the LS group 
compared to DD2 (58.8 vs. 87.4 ml/min/1.73 m
2
, p<0.01). CKD stage II-V was found in 82% 
of patients, of these 58% and 28% had moderate-to-severe CKD, in LS and DD2 respectively. 
Three patients (3%), all with LS developed stage 5 of CKD. Survival analysis showed that LS 
was also associated with a faster CKD progression than DD2 (p<0.01). On multivariate 
analysis, eGFR was dependent only on age (b=-0.46, p<0.001). Localization, but not type of 
mutations tended to correlate with eGFR. There was also no significant association between 
presence of nephrocalcinosis, hypercalciuria, proteinuria and number of adverse clinical 
events and CKD.  
Conclusions CKD is commonly found in children with OCRL mutations. CKD progression 
was strongly related to the underlying diagnosis but did not associate with clinical parameters, 
such as nephrocalcinosis or proteinuria.  
 
 
 
 
 
Keywords chronic kidney disease, Dent-2 disease, eGFR,  Lowe syndrome, nephrocalcinosis, 
OCRL 
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Short summary:  
The study comprises the largest, well-characterized cohort of children with OCRL mutations. 
Here, we confirmed the high prevalence of CKD in children with Lowe syndrome and Dent-2 
disease and we found a difference, not previously described, in renal outcome with respect to 
progression of CKD between these tubulopathies. Moreover, we did not identify association 
between CKD and nephrocalcinosis and proteinuria, suggesting that modifying these factors 
will have no impact on the long-term kidney function.  
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Introduction 
The oculocerebrorenal syndrome of Lowe (LS) (OMIM #309000) and its milder 
variant, Dent-2 disease (DD2) (OMIM #300555) are ultrarare X-linked disorders associated 
with mutations in OCRL, which encodes the enzyme inositol polyphosphate 5-phosphatase, 
OCRL1 [1, 2]. OCRL1 is involved in proximal tubular endocytosis and is also reported to 
play a role in the maturation of polarized epithelial cells and in cytokinesis and ciliogenesis, 
[3, 4]. Despite being caused by mutations in the same gene, LS is characterized by 
multi-organ involvement with the triad of congenital cataracts, neurological abnormalities and 
a selective tubular dysfunction of variable extent, whilst the DD2 phenotype is restricted 
mainly to a proximal tubulopathy [5-7]. The life span of an affected individual with LS rarely 
exceeds 40 years and is mainly limited by progressive kidney failure [8]. Severity of chronic 
kidney disease (CKD) is variable and the factors determining this variability remain to be 
elucidated.  
A genotype-phenotype effect has been observed in some disorders, but this has not 
been shown in LS and DD2 so far [9]. However, there is a distinct distribution of mutations 
along the OCRL gene. In DD2, most mutations have been detected 5’ of exon 8, whereas in 
classic LS, mutations concentrate in exons 8-24 [9]. Besides the extra-renal manifestations, 
there also appears to be a difference with regards to renal involvement in these two 
phenotypes in that the prevalence of renal failure is lower in patients with DD2 compared to 
LS (32% and 74% respectively)  [6].  
In the present study, we conducted retrospective analyses of genetic and clinical data 
in a large, well-characterized cohort of children with OCRL mutations. We aimed to compare 
the long-term renal outcome between the LS and DD2 groups and to investigate possible 
determinants of CKD progression, ranging from clinical factors, such as nephrocalcinosis to a 
potential genotype effect.  
 
Subjects and Methods 
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This retrospective, multicenter study was designed to collect data obtained from pediatric 
patients (< 19 years of age) with OCRL-related disorders. A spreadsheet with requested 
information was sent to clinicians. We requested the most recent data, including 
anthropometrical and biochemical parameters as well as clinical data obtained throughout the 
observation period  [presence of hypertension, episodes of dehydration, stone obstruction, 
urinary tract infections, acute kidney injuries (AKI), numbers of contrast X-ray studies, 
presumed cause of death]. Additionally, the physicians were asked to provide details of 
treatments, including height and serum creatinine before and on growth hormone (GH) 
therapy. To determine longitudinally the rate of CKD progression, height and serum 
creatinine were obtained and individually an averaged eGFR/year was calculated. 
Between September 2014 and December 2015, data on 107 patients (boys) with LS 
and DD2 were collected. Finally, due to lack of height parameter in one patient, 106 children 
were included into the analysis. Eighty eight cases (83%) presented with full 
oculo-cerebro-renal criteria, whereas the remaining patients, defined by clinicians as DD2, 
showed milder phenotype of LS (n=6; 5.7%) or exhibited renal tubulopathy only (n=12; 
11.3%). The patients originated from: Poland (n=27), Korea (n=24), Italy (n=16), UK (n=15), 
Germany (n=10), Greece (n=6), Macedonia (n=3), and Kazakhstan, Malta, Serbia, Slovenia, 
Sweden (n=1, each). 
 eGFR was calculated using the original Schwartz method [10], but with a revised 
k-value of 26 (when serum creatinine in µmol/l) for patients with LS as suggested previously 
[5]. The subject's severity of CKD was classified by strata defined by the National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) CKD staging system [11], 
taking into account physiologically lower GFR in children < 2 years [12]. 
Urine analysis was performed on spot samples and calciuria, phosphaturia, glycosuria, 
aminoaciduria, untimed proteinuria, creatininuria, and low-molecular weight proteinuria 
(LMWP) was determined by dipstick and/or formal local laboratory methods. Calciuria and 
proteinuria was also assessed by 24-hour urine collection in some patients. Calcium excretion 
> 4 mg/kg/24 h was classified as hypercalciuria, as well as an elevated calcium-creatinine 
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ratio (Ca/Cr; mg/mg) in a spot urine sample with age-appropriate references [13]. 
Hyperphosphaturia was designated as the presence of a decreased tubular reabsorption of 
phosphate (< 80%) or tubular maximum for phosphate reabsorption normalized to the 
age-appropriate lower limit of normal [14]. Hypoalbuminemia was defined as serum albumin 
< 35 g/l and hyperparathyroidism as serum intact parathyroid hormone > 66 pg/ml. Plasma 
bicarbonates, phosphate and potassium values were assessed and acidosis, hypophosphatemia 
and hypokalemia were defined when receiving supplementation or/and with decreased blood 
levels, i.e. for acidosis < 22 mmol/l  [15], for hypophosphatemia [15], and for potassium < 3.5 
mmol/l. Fanconi syndrome was recognized when a constellation of proximal renal tubular 
abnormalities was present (i.e. LMWP, hypercalciuria, acidosis, glycosuria, aminoaciduria 
and hypophosphatemia).  
Urinary protein-to-creatinine ratio (P/Cr; mg/mg) and daily protein excretion assessed 
in 24-h urine collection (mg/m
2
/h) were used to define level of proteinuria. Patients were 
identified as having normal ratios (P/Cr < 0.2), significant proteinuria (P/Cr 0.2 – 2), or high 
grade proteinuria (P/Cr > 2). Daily proteinuria was graded into 3 groups: < 4 mg/m
2
/h, 4-40 
mg/m
2
/h, and > 40 mg/m
2
/h. In a few cases (n=13), only dipstic proteinuria was available and 
was graded as 1+ (closest to 30 mg/dl), 2+ (closest to 100 mg/dl), 3+ (closest to 300 mg/dl), 
and 4+ (> 2000 mg/dl). To integrate the different categories of proteinuria submitted by the 
various centers, we adopted a grading system (grade 0 – P/Cr ratio < 0.2 or < 4 mg/m
2
/h or < 
1+; grade 1 – P/Cr ratio 0.2-2 or 4-40 mg/m
2
/h or 2+; grade 2 - P/Cr ratio > 2 or > 40 mg/m
2
/h 
or 3+/4+) [16]. 
Nephrocalcinosis and nephrolithiasis were assessed from ultrasound and/or CT/X-ray  
reports. Height and body mass index (BMI) data in the European children were transformed 
into standard deviation scores (SDS) with reference to the World Health Organization growth 
charts (http://www.who.int/growthref/en). For children of Asian ethnicity, SDS data were 
reported directly by the treating physicians. Short stature was defined as height SDS < -2. 
For the genotype-phenotype analysis, we grouped mutations according to the 
following criteria: 1. the expected effect on the protein product (i.e. missense, unlikely to 
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cause complete lack of protein production, and truncated mutations, which comprise 
nonsense, frameshift, splice-site mutations and exonic deletions, assumed to produce no or a 
truncated protein product) [9]. 2. the localization/position of mutations, i.e. mutations were 
analyzed with respect to recognized functional OCRL1 domains [i.e. exons 2-5 for pleckstrin 
homology domain (PH); exons 9-15 for a central 5-phosphatase domain; exons 16-20 for 
ASPM-SPD2-Hydin (ASH); and exons 21-24 for Rho GTPase activating (RhoGAP) domain] 
[9]. 
 
Statistical analysis 
Data were presented as a mean (standard deviation) or as median (upper/lower quartiles) as 
appropriate for continuous variables and as absolute numbers and/or percentages for 
categorical variables. One-way ANOVA and unpaired t test were used to analyze the data 
with normal distribution and homogeneous variances. The data that did not follow a Gaussian 
distribution were analyzed with Mann-Whitney U test or the Kruskal-Wallis test and the 
Dunn’s post-hoc test. The relationship between variables was analyzed with the Spearman’s 
rank correlation coefficient and by multivariate linear regression. Categorical data were 
analyzed with the χ2 test or the Fisher-Freeman-Halton test. For the longitudinal analysis, a 
median of all available eGFR for all patients at each age (1-19 years) was calculated and was 
shown as trend lines over time (details are provided in supplementary Figure and 
supplementary Table 1).  The age of eGFR decline (break-point) was calculated by means of 
piecewise linear regression. CKD progression was analyzed by the Kaplan-Meier method in a 
univariate analysis. The end-point was the first measurement of eGFR < 60 ml/min/1.73 m
2
. 
Data were censored at the last available eGFR measurement. and differences between 
subgroups were assessed by the log-rank test. All results were considered significant at 
p<0.05. Statistical calculations were performed using STATISTICA 10.0 PL (StatSoft Polska, 
Kraków, Poland). 
 
Results 
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The characteristics of 106 children (all boys) from 97 families are displayed in Table 1. The 
median age at last follow-up was 10 years (5.9; 16 yrs) and was similar between the LS and 
DD2 groups. The frequencies of abnormalities of tubular function reflected previous studies 
[5, 6, 17] and were as follows: LMWP (100%), hypercalciuria (80%), nephrocalcinosis 
(52%), nephrolithiasis (24%), metabolic acidosis (68%), hypophosphatemia (44%), 
hypokalemia (20%), aminoaciduria (65%) and glycosuria (16%). An apparent complete renal 
Fanconi syndrome was identified in only six patients with LS (5.7%). Short stature was noted 
in 84% of patients when compared to a normal population. As expected, subjects with LS 
were shorter than those with DD2 (median height SDS: -3.98 vs. -2.11, p<0.001). Moreover, 
phosphate wasting and acidosis were observed more frequently in LS than in DD2 (see Table 
1).  
All patients presented with proteinuria. As LMWP was not reported/determined in all 
patients this parameter was not studied in detail. Twenty percent of children had significant 
proteinuria (grade 1 in 16/82 patients), and the rest of the patients had severe proteinuria 
(grade 2 in 66/82 patients). Urinary P/Cr ratio was commonly used for the assessment of 
proteinuria in our cohort (n=63). The median P/Cr ratio was 3.9 mg/mg (2.7; 7.1), and was 
greater in patients with LS compared to DD2 (p<0.0001). Notably, P/Cr ratio did not 
correspond either to the severity of CKD or eGFR. Importantly, this parameter highly 
correlated with BMI SDS (r=-0.58, p<0.0001). 
  
Clinical course and causes of death 
Ten patients (9.4%) experienced at least one episode of urinary tract infection (9 patients had 
recurrent infections, i.e. > 2 episodes), 18 patients (17%) had one episode of dehydration 
requiring hospitalization (7 patients had ≥ 2 episodes), 11 patients (10.4%) had AKI and 3 
patients (2.8%) urinary stone obstruction. These events were almost exclusively present in 
patients with LS, except 2 episodes of dehydration in one patient with DD2. Seventeen 
individuals (16%) underwent contrast X-ray studies.  
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Four patients (3.7%) died in the analyzed cohort (the genotypes of three patients are 
shown in Table 2 in suppl.). In one previously reported patient (ls13) [17], death occurred at 
the age of 18 months and was related to pneumonia, while the other three patients died at later 
ages: one (ls25.2; 11.5 years) due to apnea/deep acidosis, and the other two, including the 
patient ls25.4 (17-18 years) due to sudden death of unknown causes. Notably, the two patients 
(ls25.2 and ls25.4) were from the same family (cousins) and had the same complex genotype 
described in detail elsewhere [17]. 
 
Chronic kidney disease 
Median eGFR was lower in the LS group compared to DD2 (58.8 vs. 87.4 ml/min/1.73 m
2
, 
p<0.01). CKD stage II-V was found in the majority of patients (74%) when analyzed the 
entire age range and was evident in 82% of patients, when the analysis was restricted to those 
> 2 years (n=97). Overall, nearly half of the patients (49%) had moderate (eGFR 30-59 
ml/min/1.73 m
2
) and 9.3% severe CKD (eGFR < 30 ml/min/1.73 m
2
). Moderate-to-severe 
CKD was more common in LS compared to DD2 (58% vs. 28%). End-stage kidney disease 
(ESKD) was found only in LS individuals. Two patients (ls66 and ls76), who developed 
ESKD at ages of 14 and 16 years respectively, harboured mutations in exon 22 (p.Arg822* 
and p.Glu806Asp, respectively), while the third patient (ls25.4) with ESKD at the age of 17 
years, had a complex mutation in exon 14/intron 14 (p.Arg486Serfs). Importantly, his cousin 
(ls25.3) with the same genotype had severe CKD (eGFR of 15.5 ml/min/1.73 m
2
) (Table 2 in 
suppl.).  
In the univariate analysis (Table 2), there was a significant relationship between eGFR 
and Ca/Cr ratio (r=0.32, p<0.01) as well as between eGFR and age in the whole group (r=-
0.5, p<0.0001; Figure 1). After the multivariate analysis, only age remained significantly 
correlated (b=-0.46, p<0.001). Both age and Ca/Cr corresponded also with CKD stages. The 
presence of nephrocalcinosis, hypercalciuria, proteinuria, the number of adverse clinical 
events (mentioned above) and contrast X-ray studies had no evident effect on renal function. 
Height SDS was highly correlated with bicarbonate levels (r=0.35, p<0.0001) and the patients 
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with uncorrected acidosis were significantly shorter than their counterparts without acidosis 
(height SDS: -4.08 vs. -3.03, p<0.0001). 
In the longitudinal analysis, in children with LS eGFR linearly falls with age and a 
clear break-point of eGFR decline occurs at the age of 10 years, whereas in subjects with 
DD2 eGFR remained stable during childhood (Figure 2 and supplementary Figure). Renal 
survival censored by Kaplan-Meier analysis showed that LS was also associated with a faster 
progression to stage 3 of CKD (p<0.01; Figure 3A).  
 
Treatment 
Table 1 summarizes participants’ treatment characteristics. The analysis of therapy in our 
group showed variable treatments. Overall, acidosis was treated in 57% of patients with alkali 
therapy, yet 49.5% remained acidotic. A third (33%) of patients were hypophosphataemic, yet 
only 23% received phosphate supplementation. Similarly, 14.4% were hypokalemic, and 13% 
received potassium supplementation. Overall, 34% of patients did not receive any treatment.  
Eleven patients (10.4%; 9 patients with LS) had been treated with GH for a median 
time of 64 months (range 30-89), and all but one had experienced an increase in height. Mean 
height SDS increased from -4.08 ± 1.30 to -3.20 ± 1.36 (p<0.001). Yet, eight patients were 
still short-statured. In DD2 patients, who had a slight growth deficiency (height SDS -2.2 and 
-2.8), their height on GH normalized. There was no apparent association with eGFR (59.7 ± 
34.8 vs. 59.4 ± 25.0 ml/min/1.73m
2
, before and after the therapy, respectively), although in 
one patient, a significant deterioration in eGFR was observed (97 vs. 35 ml/min/1.73m
2
), 
which was in excess of the expected age-associated deterioration. 
 
Analyses of OCRL Mutations 
Table in suppl. shows a summary of the mutations and their predicted effects on OCRL1 
protein.  In our study cohort, 104 patients (98%) had a molecular diagnosis, which was made 
at a median time of 2.6 years (0.8; 9.5 yrs) (Table 1), yet molecular result was not available 
for 5 patients. A total of 90 different mutations were found in the 99 mutation-positive 
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patients.  Two patients with classical features of LS and 3 patients with a clinical diagnosis of 
Dent disease had no detectable mutations in OCRL or CLCN5. We report 18 (20%) previously 
unreported mutations in 21 patients associated either with LS or DD2. The phenotypic 
features of patients harbouring novel mutations are presented in Table 3. As evident in Table 
4, the mutations are diverse. More than two thirds of patients (66.6%) carry truncating 
mutations. As demonstrated in the genogram (Figure 4) mutations are scattered throughout 
the gene, and mutations in LS locate between exons 8-24, whereas they affect exons 4-15 in 
DD2. We did not observe any OCRL mutation found in both LS and DD2. 
 
Genotype-phenotype correlation  
The median eGFR for carriers of a truncating mutation (n=66) and for a missense mutation 
(n=33) was 58.82 ml/min/1.73m
2
 (44; 82.44) and 68.4 ml/min/1.73m
2
 (54.5; 91), respectively, 
(p=0.12). The mutations were also tested for the position along the gene with the patients 
separated into 4 groups, which refer to the respective OCRL1 domains (Figure 4). The 
cross-sectional analysis showed a tendency for a decrease in eGFR along the gene (p<0.05; 
Figure 5). There were no significant differences in median ages between the analyzed 
mutational groups. Similar analyses were done by Kaplan-Meier method. Renal survival was 
not different between mutational types (p=0.24) and the mutations’ localization (p=0.36, 
Figure 3B).   
Furthermore, we observed strong inter-familial variability of eGFR. For example, 
among four patients with the same genotype (c.2464C>T; p.Arg822*), only one (ls66) had 
ESKD (14.3 yrs), whereas other two patients at similar age (11 and 16 yrs) had CKD stage 2 
and 3 respectively, and the third had normal eGFR (4.6 yrs). We also found evidence of 
significant intra-familial variation of eGFR as illustrated in one of the families (ls25) with 
four affected boys, of whom two had severe CKD, while the other two had stage 2 of CKD at 
comparable age. 
 
Discussion 
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This study presents a comprehensive analysis of molecular defects, clinical 
phenotypes, and treatments with respect to CKD. The most important finding from this 
analysis was that among OCRL patients, those diagnosed with LS have worse renal function 
than those with DD2 and a faster rate of CKD progression in LS. Whether this is related to 
genotype or to other yet unidentified factors that explain the difference between developing 
LS or DD2 remains to be determined. However, mutations that affect exons at the 3’ end of 
the gene which encode the RhoGAP domain, appear to be associated with more severe CKD. 
As mutations of subjects with DD2 localize in exons 2-15, compared to exons 8-24 in LS 
patients  [9], mutation localization does appear to correlate with disease severity. However, 
we also observed a strong inter- and intra-familial variability of eGFR in patients with the 
same mutation. Suboptimal medical treatment, which in fact was demonstrated in our study, 
might be a significant determinant of the variability. This clinical variation in renal function 
might also be explainable by the individual ability to compensate for the loss of OCRL1 
function. It has been suggested that this occurs through INPP5B, an inositol 5-phosphatase, 
which shares nearly all functional domains with OCRL1 [18]. It is questionable, however, 
whether this mechanism does explain the phenotypic differences as Montjean et al. [19] 
observed identical expression not only of OCRL, but also of INPP5B at the RNA and protein 
levels in fibroblasts from both DD2 and LS patients. On the other hand, they demonstrated an 
intermediate phenotype of DD2 fibroblasts in terms of the F-actin network, alpha-actinin, and 
primary cilia. Hence, it has been proposed a differential activity of modyfing factors might 
contribute to the clinical variability between patients. 
Slowly progressive renal failure is a hallmark of LS and DD2. However, no report 
documented the longitudinal course of renal function in patients with LS and DD2. In this 
study, we did for the first time longitudinal analyses of eGFR and found that in subjects with 
LS renal function starts to decrease at around 10 years of age, predicting ESKD in the fourth 
decade (not shown) as was originally predicted by Charnas at el. [8]. Unexpectedly, we 
demonstrated that in DD2, eGFR does not change significantly with time in childhood. 
Indeed, we are not aware of a patient with DD2 and ESKD, though the data are limited in 
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adults [4]. One might speculate that the observed decline in eGFR in LS might result simply 
from the natural deterioration of damaged nephrons, but not due to puberty, which was 
demonstrated in patients with CKD with renal hypodysplasia [20]. In this regard, the 
limitation of our study is lack of puberty status that might account for the rate of renal 
function decline. 
In this study, we showed a high prevalence of CKD. Importantly, a high percentage 
(about 50%) of our patients had moderate-to-severe CKD. As suggested by Böckenhauer et 
al. [5], we used for LS a k-value of 26, derived from the formal GFR measurements, because 
creatinine values can be misleading in patients with abnormal muscle mass. When using 
original k-values, the calculation of eGFR tends to overestimate this value, thereby resulting 
in an underappreciation of CKD, as reported in previous case series [21, 22]. This imprecision 
in measurement of eGFR might cause a high proportion of CKD patients misdiagnosed, so 
that some abnormalities and interventions related to CKD may be missed and/or delayed. In 
view of the abnormal muscle mass of these patients, cystatin C should preferably be used to 
monitor GFR in LS patients while making use of the most recent IFCC calibrated GFR 
estimating equations [4]. 
This cohort study also provides an interesting observation regarding proteinuria. Here, 
we found that the level of P/Cr ratio did not correspond with renal function. This finding calls 
into question the usefulness of this parameter in the population we studied. Importantly, this 
parameter and also urinary Ca/Cr ratio negatively correlated with BMI SDS (data not shown), 
which suggests that ratios, based on urine creatinine excretion, might be largely dependent on 
muscle mass, which is very low especially in children with LS. These parameters may be 
misleading, so that they cannot be reliably used in this group. In this regard, urinary protein to 
osmolality ratio may be preferable [23] or ideally 24-hour proteinuria, if feasible. Similarly, 
calcium to osmolality ratio may be superior to Ca/Cr ratio, as shown by Richmond at al. [24].  
Nephrocalcinosis is another factor that is suspected to contribute to CKD progression, 
but again, our data could not show any association. Importantly, since nephrocalcinosis was 
assessed by ultrasound in most our cases, there is a possibility that the term nephrocalcinosis 
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may have referred to just hyperechogenic kidneys. So, we cannot exclude the 
overrepresentation of patients with renal calcifications. On the other hand, the frequency of 
this abnormality (52%) was comparable to that reported by others [6, 17]. Interestingly, our 
data showed that LS patients are more susceptible to severe dehydration, AKI and urinary 
tract infections. These observations are important and should inform the management of these 
patients. It clearly cautions against the use of thiazides and angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers. These agents are typically prescribed to modify 
calci- and proteinuria under the assumption that these accelerate CKD progression. Yet, our 
data argue against this and the treatment could instead only predispose them to unfavorable 
events, such as dehydration and AKI. Our observations may be relevant beyond  LS/DD2, as 
we are not aware of any data in tubulopathies with nephrocalcinosis like Dent-1 disease [25], 
familial hypomagnesemia, hypercalciuria and nephrocalcinosis [26] that could evidently 
demonstrate the impact of nephrocalcinosis on the presence or progression of CKD.  
Although the complete data set of proximal abnormalities was not available for all 
patients, the large cohort allowed to get an idea on the frequency of tubular abnormalities. 
Quite surprisingly, glycosuria, which was absent in LS in the study of Böckenhauer et al. [5], 
was present in about 16% of our patients. Since this parameter was assessed by dipstick and 
not tested repeatedly, its frequency shown in our study may be misleading. One should be 
aware of the usefulness of this abnormality as this is the key finding in predicting Fanconi 
syndrome, which was in turn evident in 5.7%. Glycosuria is easy to detect in a spot urine by 
dipstick, however, in case of polyuria, a formal urine glucose determination is recommended. 
An intriguing observation is the apparently suboptimal treatment in a substantial 
portion of patients. Only 51% of our patients met K/DOQI guidelines [15] and had HCO3
-
 
level greater than 22 mmol/l. Importantly, we found a high proportion of patients with 
uncorrected acidosis, which corresponded with high frequency of growth impairment and 
CKD. Potentially, part of the growth deficiency may result from acidosis. Indeed, in our study 
in the LS group height strongly correlated with actual acidosis. Yet, no relationship could be 
disclosed between height and eGFR.  
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The limitations of our study include its retrospective and multicenter nature, which is the 
reason for missing data and for not uniform data acquisition. The relatively small number of 
patients with DD2 in comparison to LS as well as restriction of the study to children, limits 
also the power of our study to demonstrate renal survival.  
In summary, we confirmed the high prevalence of CKD in children with OCRL 
mutations and found a difference in clinical outcome with respect to progression of CKD 
associated with different OCRL phenotypes. We did not identify association between CKD 
and nephrocalcinosis and proteinuria, suggesting that modifying these factors will have no 
impact on the long-term kidney function.  
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Table 1. Characterization of the entire cohort (n=106) and the subgroups, i.e. Lowe syndrome (n=88) and Dent-2 disease (n=18). 
Parameter OCRL (all) Lowe syndrome Dent-2 disease p
a 
Range/Normal 
Ethnicity, European  81 (76%) 68 (77%) 13 (72%) ns - 
Age of last visit (year), n=106
b 
10 (5.9; 16) 9.8 (4.8; 16) 13.8 (7; 17) ns 1-18 
Age of clinical diagnosis (year), 
n=102 
0.95 (0.4; 5) 0.65 (0.3; 2) 5.95 (5; 10) < 0.0001 0.1-18.5 
Age of molecular diagnosis (year), 
n=93 
2.6 (0.8; 9.5) 1.8 (0.8; 7) 9.4 (6.2; 12) < 0.0001 0.1-19 
Height SDS, n=106 -3.74 (-5.72; -2.75) -3.98 (-6.04; -3.29) -2.11 (-3.23; -1.1) < 0.0001 -10.15÷0.47 
growth retardation 89 (84%) 80 (91%) 9 (50%) < 0.001 < -2 SDS 
BMI SDS, n=99 0.55 (-0.8; 1.68) 0.55 (-1.21; 1.52) 0.85 (0.02; 2.03) ns -4.26÷2.96 
Nephrocalcinosis, n=104 54 (52%) 45 (52%) 9 (50%) ns - 
Nephrolithiasis, n=104 25 (24%) 19 (22%) 6 (33%) ns - 
Serum creatinine (µmol/l), n=106 51.6 (31.8; 77.8) 50.6 (30.9; 76) 59.2 (42.4; 107.8) ns 11.5-415.5 
eGFR (ml/1.73/m
2
), n=106 62.5 (46.2; 85.6) 58.8 (43; 83) 87.4 (56; 91.6) < 0.01 8.2-181 
CKD (> 2 years) 97 79 18 - - 
CKD stage 1 19 (19.6%) 12 (15.2%) 7 (38.9%) < 0.05 eGFR > 90 ml/1.73/m
2
 
CKD stage 2 27 (27.8%) 21 (26.6%) 6 (33.3%) ns eGFR 89-60 ml/1.73/m
2
 
CKD stage 3 42 (43.3%) 37 (46.8%) 5 (27.8%) ns eGFR 59-30 ml/1.73/m
2
 
CKD stage 4 6 (6.2%) 6 (7.6%) 0 (0%) ns eGFR 29-15 ml/1.73/m
2
 
CKD stage 5/ESKD 3 (3.1%) 3 (3.8%) 0 (0%) ns eGFR < 15 ml/1.73/m
2
 
Albuminemia (g/l), n=89 45 (43; 48) 45.0 (42.7; 47) 45.5 (43; 49.2) ns 29-56 
hypoalbuminemia 4 (4.5%) 4 (5%) 0 (0%) ns < 35 g/l 
Serum phosphate (mmol/l), n=103 1.27 (1.07; 1.49) 1.23 (1.03; 1.42) 1.42 (1.29; 1.58) < 0.05 0.31-2.02 
hypophosphatemia 45 (44%) 45 (52%) 0 (0%) < 0.001 
Phosphate level [15] or 
phosphates 
supplemention 
actual hypophosphatemia 34 (33%) 34 (39.5%) 0 (0%) < 0.05 Phosphate level [15] 
Hyperphosphaturia, n=68 34 (50%) 33 (57%) 1 (10%) < 0.05 TRP > 80% or 
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TmP/GFR [14] 
Bicarbonate concentration 
(mmol/l), n=101 
22 (19; 24) 21 (19; 23.9) 24.4 (23; 25) < 0.0001 13.7-33 
acidosis 69 (68%) 66 (79.5%) 3 (17%) < 0.0001 
HCO3
- 
< 22 mmol/ or 
alkali supplementation 
actual acidosis 50 (49.5%) 49 (59%) 1 (5.5%) < 0.001 
HCO3
- 
< 22 mmol/l 
[15] 
Serum potassium (mmol/l), n=104 4.0 (3.6; 4.2) 4.0 (3.6; 4.2) 4.1 (3.9; 4.2) ns 2.7-5.8 
hypokalemia 21 (20.2%) 20 (23%) 1 (5.5%) ns 
potassium < 3.5 or 
potassium 
supplementation 
actual hypokalemia 15 (14.4%) 15 (17%) 0 (0%) ns > 3.5 mmol/l 
iPTH (pg/ml), n=76 31.7 (17.8; 52.5) 36.9 (18; 53.5) 21.3 (10.9; 38.4) ns 2.8-174 
hyperparathyroidism 11 (14.5%) 10 (16%) 1 (8%) ns > 66 pg/ml 
Proteinuria    - - 
LMWP, n=77 77 (100%) 60 (100%) 17 (100%) ns - 
dipstic proteinuria (mg/dl), n=13 154 (111; 170) 154 (111; 170) - - 50-513 
P/Cr ratio (mg/mg), n=63 3.9 (2.7; 7.10) 4.8 (3.3; 7.6) 2.2 (1.6; 3.6) < 0.0001 0.3-16.7 
P/Cr ratio 0.2-2.0 9 (14%) 3 (6.4%) 6 (37.5%) 
< 0.01 
- 
P/Cr ratio > 2.0 54 (86%) 44 (93.6%) 10 (62.5%) - 
daily excretion of protein (mg/m
2
/h), 
n=18 
45 (28.7; 68) 42 (12.5; 84) 48 (40; 58) ns 8-100; < 4 mg/m
2
/h 
Proteinuria grading 82 65 17 
ns 
- 
grade 1  16 (20%) 13 (20%) 3 (18%) - 
grade 2  66 (80%) 52 (80%) 14 (82%) - 
Hypercalciuria, n=95 76 (80%) 64 (83%) 12 (67%) ns - 
daily excretion (mg/kg/24 h), n=8 6.0 (4.6; 7.05) 6.2 (4.6; 7.5) 4.5 (4.5; 4.5) ns 2.4-8.9; < 4 mg/kg/24 h 
Ca/Cr ratio (mg/mg), n=87 0.39 (0.29; 0.66) 0.46 (0.3; 0.74) 0.38 (0.15; 0.44) < 0.05 0.09-1.68; [13] 
Glycosuria, n=104 17 (16%) 13 (15%) 4 (22%) ns - 
Aminoaciduria, n=77 50 (65%) 46 (78%) 4 (22%) ns - 
Fanconi syndrome, n=106 6 (5.7%) 6 (6.8%) 0 (0%) ns - 
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Hypertension, n=106 0 (0%) 0 (0%) 0 (0%) ns - 
Death, n=106 4 (3.8%) 4 (4.5%) 0 (0%) ns - 
Treatments     - 
alkali therapy 60 (57%) 58 (66%) 2 (11%) < 0.001 - 
bicarbonates supplementation 45 (42%) 45 (51%) 0 (0%) < 0.001 - 
citrates supplementation 40 (38%) 38 (43%) 2 (11%) < 0.05 - 
phosphate supplementation 24 (23%) 24 (27%) 0 (0%) < 0.05 - 
potassium supplementation 13 (13%) 12 (14%) 1 (5.5%) ns - 
thiazides 7 (7%) 6 (6.8%) 1 (5.5%) ns - 
ACE/ARB 17 (16%) 15 (17%) 2 (11%) ns - 
vitamin D 30 (28%) 30 (34%) 0 (0%) < 0.05 - 
GH 11 (10.4%) 9 (10%) 2 (11%) ns - 
not treated 36 (34%) 22 (25%) 14 (78%) < 0.001 - 
Data are given as median and lower/upper quartiles/range (continuous variables) or as absolute numbers and percentages (categorical variables) 
a
 p statistical differences between patients with Lowe syndrome and Dent-2 diesease 
b 
number (percentage) of patients/number of available data  
 
Abbrevations: SDS, standard deviation score; BMI, body max index; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; ESKD, 
end-stage renal disease; TRP; tubular reabsorption of phosphate; TmP/GFR, tubular maximum for phosphate reabsorption; iPTH, intact parathyroid 
hormone; LMWP, low-molecular weight proteinuria; P/Cr ratio, protein-to-creatinine; Ca/Cr ratio, calcium-to-creatinine; ACE, angiotensin-converting 
enzyme inhibitors; ARB, angiotensin receptor blocker; GH, growth hormone; ns, not significant 
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Table 2. Univariate correlations between eGFR and other variables in the entire cohort. 
Variable Correlation 
coefficient 
p 
Age -0.5 < 0.0001 
Age of clinical diagnosis -0.06 0.57 
Age of molecular diagnosis -0.20 0.10 
Height SDS 0.05 0.57 
BMI SDS -0.2 0.05 
Bicarbonate concentration -0.12 0.24 
Albuminemia -0.13 0.19 
Serum phosphate 0.02 0.82 
Serum potassium 0.09 0.38 
iPTH 0.00 0.99 
P/Cr -0.06 0.64 
Ca/Cr 0.32 < 0.01 
Abbrevations: eGFR, estimated glomerular filtration rate; SDS, standard 
deviation score; BMI, body max index; iPTH, intact parathyroid 
hormone; P/Cr ratio, protein-to-creatinine; Ca/Cr ratio, 
calcium-to-creatinine 
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Table 3. Clinical and molecular characterization of patients with 18 novel mutations. 
Patient Age
a
  Location  Mutation
b
 
 
Consequence
b
 
 Cataract/ 
glaucoma 
Neurological 
symptoms  
Renal symptoms
c 
other 
features 
NC/NL HC Ac P  Gly  AA FS eGFR 
d13 5.9 exon 4 c.214_215delCT p.Leu72Phefs*2 n/n n n/n y n n n  N/D n 90 - 
d7 18 exon 5 c.260delA p.Gln87Argfs*19 n/n N/A n/n n n n n N/D n 70 - 
d6 6.2 exon 5 c.260delA p.Gln87Argfs*19 n/n N/A n/n y n n n N/D n 85 - 
ls38 9 exon 8 c.621_624delGAAG p.Lys208Serfs*31 y/y N/A n/n  N/A y y n  n n 44  - 
ls29 14 exon 9 c.724_729insT p.Val/244Cysfs*12 y/y N/A n/n y y y n n n 55  - 
ls8 10 exon 9 c.724_729insT p.Val244Cysfs*12 y/n HP, DD y/n y y y n y n 56  - 
ls4 2 exon 9 c.812T>A p.Ile271Asn y/y HP, DD n/n y y y y y y 113 
rickets, facial 
dysmorphia 
ls12 15.5 exon 11 c.943C>T p.Gln315* y/y DD y/n n y y n y n 59 
rickets, facial 
dysmorphia 
d12 5 exon 11 c.953G>T p.Arg318Leu n/n n y/y y y n n  n n 90 - 
ls75 2.6 exon 12 c.1067G>A p.Gly356Asp y/n HP, DD n/y y n y n n n 98 cholestasis 
d8.1
d 
9 exon 12 c.1133C>T p.Ala378Val n/n n  y/y y n n n  N/D n 130 - 
d8.2
d 
7 exon 12 c.1133C>T p.Ala378Val n/n n n/n n n n n  N/D n 143 -  
ls41 1 exon 15 c.1539T>G p.Tyr513* y/y N/A  N/A N/A  y n n  N/D n 68  - 
ls44 17 intron 15 c.1603-2A>C splice defect y/n N/A y/n y n y n N/D n 50 - 
ls72 1.2 exon 17 c.1817insA p.Asn606Lysfs*1 y/n HP, DD n/n n y y n y n 68 
rickets, facial 
dysmorphia 
ls7 7 exon 21 c.2313T>A p.Cys771* y/y HP, DD y/n y y n n y n 80  - 
ls71 7 intron 21 c.2341+1G>C splice defect y/n  DD n/n y n n n y n 90 
facial 
dysmorphia 
ls10 15 exon 22 c.2455del C p.Arg819Glyfs*5 y/n HP, DD y/n n y y n y n 49  - 
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ls6.1
e
 17 intron 23 c.2581+1G>A splice defect y/n N/A y/n y y n n y n 37 - 
ls6.2
e
 17 intron 23 c.2581+1G>A splice defect y/n N/A y/n y y y n n n 34 - 
ls73 1.5 exons 1-2 deletion - y/n HP, DD y/y n y y n y n 61 rickets 
a 
age at the last observation 
b 
numbering according to the cDNA sequence (GenBank NM_000276.3) with the A of the first coding methionine as no. 1
 
c 
all patients have low-molecular weight proteinuria 
d 
Patients d8.1 and d8.2 are brothers 
e
 Patients d6.1 and d6.2 are cousins 
 
Abbrevations: NC, nephrocalcinosis; NL, nephroloithiasis; HC, hypercalciuria; Ac, metabolic acidosis; P, hypophosphatemia; Gly, glycosuria; AA, aminoaciduria; 
FS, Fanconi syndrome; eGFR, estimated glomerular filtration rate; HP, muscular hypotonia; DD, developmental delay; N/A, not applicable; N/D, not done 
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Table 4. Type of mutations in the OCRL cohort. 
 Type of mutations 
Number of 
patients 
Number of 
novel mutations 
L
o
w
e 
sy
n
d
r
o
m
e
 
missense 23 1 
nonsense 29 3 
splice site 13 1 
deletion (large 
deletion) 
8 (3) 3 (1) 
insertion 4 3 
insertion/deletion 4 - 
total, n (%) 81 (81.8%)
a 
11 (73.3%) 
D
e
n
t-
2
 d
is
e
a
se
 
missense 10 3 
nonsense - - 
splice site - - 
deletion 4 1 
duplication - - 
insertion 4 - 
insertion/deletion - - 
total, n (%) 18 (18.2%)
a 
4 (26.7%) 
Suspected 
Lowe 
syndrome – 
no mutation 
identified
b 
 
2 - 
No genotype 
 5 - 
Total 
 106 (100%) 15 (100%) 
a 
percentage of all patients with known genotype (n=99) 
b 
negative for CLCN5/OCRL mutations 
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Legends to figures 
Figure 1. A scatter plot of eGFR versus age in children with Dent-2 disease (squares) and 
Lowe syndrome (black dots) (r=-0.5, p<0.0001, for the entire group). 
 
Figure 2. Longitudinal analysis of renal function in children with Dent-2 disease (left panel) 
and Lowe syndrome (LS; right panel). An arrow indicates a break-point of eGFR decline in 
LS (10 years of age). 
 
Figure 3. A comparison of chronic kidney disease (CKD) progression analyzed by 
Kaplan-Meier survival with the end-point at stage 3 of CKD between children with Lowe 
syndrome and Dent-2 disease (p<0.01) (A), and between patients carring mutations with 
respect to the functional OCRL1 domains (B; p=0.36), (PH, pleckstrin homology; 5P, 
5-phosphatase; ASH, ASPM-SPD2-Hydin; RhoGAP, Rho GTPase activating). 
 
Figure 4. Distribution of mutations (at DNA level) in the OCRL gene in our patients with 
Lowe syndrome (n=81) and Dent-2 disease (n=18) (above and below the genogram, 
respectively). The boxes represent the exons (not to scale). Intronic mutations are indicated in 
bold, while horizontal line show gross genomic deletions (del). The domains are shown below 
respective, coding exons (PH, pleckstrin homology; 5-phosphatase; ASH, 
ASPM-SPD2-Hydin; RhoGAP, Rho GTPase activating). *familial mutations; **recurrent 
mutations; #novel mutations; §a complex mutation described elsewhere [17] 
 
Figure 5. The differences in eGFR across the OCRL gene by affected domains [exons 2-5 
(PH domain, n=6); exons 9-15 (5-phosphatase domain, n=46); exons 16-20 (ASH domain, 
n=19); exons 21-24 (RhoGAP domain, n=19)] (Kruskal-Wallis test, p<0.05). The patients 
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harbouring mutations in exons 9-16 had higher median eGFR versus those with mutations in 
exons 21-24 (Mann-Whitney U test, p<0.01).  
 
Figure (suppl.) Raw data of eGFR in children with LS. To determine longitudinally the rate 
of CKD progression, height and serum creatinine were collected and when more than one 
measure was available, individually an averaged eGFR/year was calculated (a point in 
supplementary Figure). Since the data were obtained at different time points, a median of all 
available eGFR for all patients on a yearly basis (ages 1-19 years) was calculated 
(supplementary Table 1). The age of eGFR decline (break-point) was calculated by means of 
piecewise linear regression. 
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Figure 1. 
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Figure 2. 
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Figure 3A. 
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Patients at risk 
(n)/Age (years) 3 4.8 6.6 8.3 10.1 11.9 13.7 15.4 17.2 19 
   PH domain 5 4 4 2 1 1 1 1 1 1 
   5P domain 43 33 29 24 20 16 12 7 4 3 
  ASH domain 18 13 11 9 9 7 6 4 3 1 
  RhoGAP domain 19 14 12 10 7 7 4 3 1 0 
 
Figure 3B. 
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Figure 5. (corrected) 
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